Skip to content

Author

R. Zeiser

We have 14 of 606 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Gp120-Activated Allogeneic Regulatory T cells for Prevention of Graft-versus-Host-Disease - a First-in-Human Trial.

These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.

A. Tuettenberg, L. Ruhnke, J. Schlöder et al. · 0 citations
Open access Aug 2026

Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.

Pegtarazimod reduced aGVHD in mice by suppressing pro inflammatory neutrophil effector functions and preserving enterocyte integrity and the clinical trial data support tolerability of pegtarazimod in aGVHD patients and further studies are needed to determine efficacy.

Verena Holzmüller, Jana Gawron, Ann-Cathrin Burk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.